In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 70 for your search:
Drug:  dasatinib
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-400, 2011-006180-21, NCT01660906

2.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 4443, 2007-006185-15, ISRCTN54923521, NCT01460693

3.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: AMLSG 21-13, NCT02013648

4.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 08-122, NCT00820170

5.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCLL084993, NCT00829647

6.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000637854, NCCTG-N0877, N0877, NCT00869401

7.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: J08101, CA180123, NCT00882583

8.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GEICAM/2010-04, NCT01306942

9.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0333, CA180357, NCI-2012-00014, NCT01498445

10.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PRI-724-201, NCT01606579

11.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2011-203, NCT01609816

12.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2011-204, NCT01643603

13.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-0697, NCT01751425

14.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: 12393, NCI-2013-01141, P30CA033572, NCT01876953

15.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005-0422, NCI-2012-01317, NCT00254423

16.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000598300, E2607, ECOG-E2607, NCT00700882

17.

Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 21
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-226, 2008-002260-33, NCT00777036

18.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NCCTG-N0872, NCI-2011-01921, CDR0000641746, N0872, NCT00892177

19.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0809009979, NCT00918463

20.

Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CA 180-287, NCT00979160

21.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: D'Accord study, NCT01051115

22.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-325, NCT01173679

23.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 50 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02621, CDR0000690286, CALGB-10701, CALGB 10701/CTSU C10701, U10CA031946, P30CA014236, NCT01256398

24.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0070, NCI-2011-00267, NCT01254864

25.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DASA-TRAS, NCT01310010
1    
New Search